InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

FENNEC PHARMACEUTICALS INC.

FENC Clue Score47
United States Fiscal year ends December CIK 0001211583
$10.71 +0.75% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $10.71 +15.29% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue0.0Operating income−2.9Net income−2.8Fiscal year 2017Revenue0.0Operating income−7.0Net income−7.0Fiscal year 2018Revenue0.0Operating income−10.4Net income−9.9Fiscal year 2019Revenue0.0Operating income−13.0Net income−12.8Fiscal year 2020Revenue0.2Operating income−17.9Net income−18.1EPS, diluted−0.76Fiscal year 2021Operating income−17.2Net income−17.3EPS, diluted−0.67Fiscal year 2022Revenue1.5Operating income−22.6Net income−23.7EPS, diluted−0.90Fiscal year 2023Revenue21.3 +1,284.5%Operating income−12.8Net income−16.0EPS, diluted−0.60Fiscal year 2024Revenue47.5 +123.7%Operating income2.6Net income−0.4EPS, diluted−0.02Fiscal year 2025Revenue44.6 −6.1%Operating income−6.3Net income−9.7EPS, diluted−0.34
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.0 0.0 0.0 0.2 n/a 1.5 21.3 47.5 44.6
Growth +1,284.5% +123.7% −6.1%
Operating income −2.9 −7.0 −10.4 −13.0 −17.9 −17.2 −22.6 −12.8 2.6 −6.3
Net income −2.8 −7.0 −9.9 −12.8 −18.1 −17.3 −23.7 −16.0 −0.4 −9.7
Growth
EPS, diluted n/a n/a n/a n/a −0.76 −0.67 −0.90 −0.60 −0.02 −0.34

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Operating margin−10,520.6%Net margin−10,652.4%Fiscal year 2021Fiscal year 2022Gross margin94.4%Operating margin−1,471.6%Net margin−1,544.9%Fiscal year 2023Gross margin94.1%Operating margin−60.1%Net margin−75.5%Fiscal year 2024Operating margin5.4%Net margin−0.9%Fiscal year 2025Operating margin−14.1%Net margin−21.8%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Gross margin n/a n/a n/a n/a n/a n/a 94.4% 94.1% n/a n/a
Operating margin n/a n/a n/a n/a −10,520.6% n/a −1,471.6% −60.1% 5.4% −14.1%
Net margin n/a n/a n/a n/a −10,652.4% n/a −1,544.9% −75.5% −0.9% −21.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2016Operating cash flow−2.1Fiscal year 2017Operating cash flow−3.6Fiscal year 2018Operating cash flow−7.8Fiscal year 2019Operating cash flow−9.1Fiscal year 2020Operating cash flow−15.6Fiscal year 2021Operating cash flow−14.2Fiscal year 2022Operating cash flow−18.1Fiscal year 2023Operating cash flow−17.1Fiscal year 2024Operating cash flow27.0Fiscal year 2025Operating cash flow−12.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −2.1 −3.6 −7.8 −9.1 −15.6 −14.2 −18.1 −17.1 27.0 −12.5

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Cash3.9Shareholders’ equity3.6Fiscal year 2017Cash28.3Shareholders’ equity26.8Fiscal year 2018Cash22.8Shareholders’ equity21.3Fiscal year 2019Cash13.7Shareholders’ equity11.9Fiscal year 2020Cash30.3Shareholders’ equity29.1Fiscal year 2021Cash21.1Total debt5.0Net cash (debt)16.1Shareholders’ equity15.8Debt to equity0.32Fiscal year 2022Cash23.8Total debt24.9Net cash (debt)−1.1Shareholders’ equity−2.6Fiscal year 2023Cash13.3Total debt30.9Net cash (debt)−17.7Shareholders’ equity−11.6Fiscal year 2024Cash26.6Total debt19.3Net cash (debt)7.3Shareholders’ equity−5.9Fiscal year 2025Cash36.8Shareholders’ equity35.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 3.9 28.3 22.8 13.7 30.3 21.1 23.8 13.3 26.6 36.8
Total debt n/a n/a n/a n/a n/a 5.0 24.9 30.9 19.3 n/a
Net cash (debt) n/a n/a n/a n/a n/a 16.1 −1.1 −17.7 7.3 n/a
Shareholders’ equity 3.6 26.8 21.3 11.9 29.1 15.8 −2.6 −11.6 −5.9 35.5
Debt to equity n/a n/a n/a n/a n/a 0.32 n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020† 31 Dec 2020 FY2021† 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.0 0.0 0.0 0.0 0.2 n/a 1.5 21.3 47.5 44.6
Growth +1,284.5% +123.7% −6.1%
n/a n/a n/a n/a n/a n/a 0.1 1.3 n/a n/a
n/a n/a n/a n/a n/a n/a 1.4 20.0 n/a n/a
Growth +1,279.8%
0.5 1.9 5.0 5.6 5.1 5.0 3.5 0.1 0.3 0.3
2.4 5.0 5.4 7.4 13.0 12.2 17.7 20.6 23.1 28.3
−2.9 −7.0 −10.4 −13.0 −17.9 −17.2 −22.6 −12.8 2.6 −6.3
Growth −344.6%
−2.8 −7.0 n/a n/a n/a n/a n/a −16.0 −0.1 −9.6
0.0 0.0 0.0 0.0 0.0 0.0 0.0 n/a 0.4 0.1
−2.8 −7.0 −9.9 −12.8 −18.1 −17.3 −23.7 −16.0 −0.4 −9.7
Growth
Per share
n/a n/a n/a n/a −0.76 −0.67 −0.90 −0.60 −0.02 −0.34
n/a n/a n/a n/a −0.76 −0.67 −0.90 −0.60 −0.02 −0.34
Growth
12.8 15.0 18.9 19.9 0.0 26.0 26.3 26.6 27.3 28.6
12.8 15.0 18.9 19.9 0.0 26.0 26.3 26.6 27.3 28.6
Growth +17.6% +26.2% +5.0% −99.9% +109,611.4% +1.0% +1.1% +2.7% +4.7%

† The diluted share count jumps at 2020 and 2021, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 10 of 10 years on file.